Comphya Closes Oversubscribed CHF 7.5 Million Series A Round to Advance U.S. and Australian Clinical Programs Following Strong Pilot Data

- IDE approval obtained; U.S. pilot study clinical site launched at Johns Hopkins- Series B round in planning to support pivotal U.S. trial- New CEO appointment signals next phase of growth and expansion

LAUSANNE, Switzerland, July 08, 2025 (GLOBE NEWSWIRE) -- Comphya SA, a clinical-stage MedTech company pioneering the first implantable neurostimulation therapy for erectile dysfunction (ED) unresponsive to medication, today announced the closing of an oversubscribed Series A financing round. Including the conversion of existing convertible loans, the round brings Comphya's total equity raised to CHF 7.5 million (~USD 8.4 million).

"We are thrilled to have the continued confidence of our investors, which enables us to accelerate our mission to bring a transformative solution to men living with erectile dysfunction following treatment for prostate cancer," said Pim van Wesel, CEO of Comphya. "With our U.S. pilot study underway and preparations beginning for a pivotal clinical trial, we're entering an important new chapter in our development."

Proceeds from the Series A will be used to:

Launch and execute a U.S. pilot study, with the first site activated at Johns Hopkins following FDA Investigational Device Exemption (IDE) approval announced in January 2025.

Prepare for a pivotal U.S. clinical trial planned for 2026, including regulatory and operational groundwork.

Expand Comphya's ongoing clinical trial in Australia, ...